Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Cwm LLC

Cwm LLC boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 92.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,080 shares of the specialty pharmaceutical company’s stock after buying an additional 1,479 shares during the quarter. Cwm LLC’s holdings in Supernus Pharmaceuticals were worth $97,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new stake in Supernus Pharmaceuticals during the 1st quarter worth approximately $41,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Supernus Pharmaceuticals during the 1st quarter worth approximately $46,000. GAMMA Investing LLC lifted its holdings in Supernus Pharmaceuticals by 116.7% during the 2nd quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 1,541 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Supernus Pharmaceuticals during the 1st quarter worth approximately $103,000. Finally, State of Wyoming lifted its holdings in Supernus Pharmaceuticals by 58.8% during the 1st quarter. State of Wyoming now owns 4,754 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 1,761 shares in the last quarter.

Insider Activity

In other news, CEO Jack A. Khattar sold 140,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the transaction, the chief executive officer directly owned 1,030,183 shares in the company, valued at $43,288,289.66. The trade was a 11.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Frank Mottola sold 14,000 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00. Following the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $689,726.96. This trade represents a 47.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 362,741 shares of company stock valued at $16,390,592. 8.80% of the stock is owned by insiders.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $55.13 on Friday. The stock has a market capitalization of $3.09 billion, a P/E ratio of 47.94 and a beta of 0.78. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $57.65. The company’s fifty day moving average is $48.02 and its two-hundred day moving average is $38.83.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on SUPN shares. Bank of America started coverage on shares of Supernus Pharmaceuticals in a report on Wednesday. They set a “buy” rating and a $65.00 target price on the stock. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a report on Tuesday, September 30th. TD Cowen raised their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. Finally, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $63.25.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.